Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEN2501 in Platinum-Resistant Ovarian Cancer
NCT07226427Phase 1Recruiting
- Sponsor
- Stemline Therapeutics
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of MEN2501 in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by Stemline Therapeutics. Primary endpoints: Dose-limiting Toxicities at 28 days and Recommended Phase 2 Dose at 6 months. Started Jan 2026; status: recruiting.
02
Drugs
MEN2501
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT07226427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07226427.